Display options
Cite
Gong Y, Li Y, Sun Q. Probiotics improve efficacy and tolerability of triple therapy to eradicate Helicobacter pylori: a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2015;8(4):6530-43
Gong, Y., Li, Y., & Sun, Q. (2015). Probiotics improve efficacy and tolerability of triple therapy to eradicate Helicobacter pylori: a meta-analysis of randomized controlled trials. International journal of clinical and experimental medicine, 8(4), 6530-43.
Gong, Yi, et al. "Probiotics improve efficacy and tolerability of triple therapy to eradicate Helicobacter pylori: a meta-analysis of randomized controlled trials." International journal of clinical and experimental medicine vol. 8,4 (2015): 6530-43.
Gong Y, Li Y, Sun Q. Probiotics improve efficacy and tolerability of triple therapy to eradicate Helicobacter pylori: a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2015 Apr 15;8(4):6530-43. eCollection 2015. PMID: 26131283; PMCID: PMC4483842.
Copy Download .nbib Format: NLM
Share it on

Int J Clin Exp Med. 2015 Apr 15;8(4):6530-43. eCollection 2015.

Probiotics improve efficacy and tolerability of triple therapy to eradicate Helicobacter pylori: a meta-analysis of randomized controlled trials.

International journal of clinical and experimental medicine

Yi Gong, Yan Li, Qian Sun

Affiliations

  1. Department of Gastroenterology, Shengjing Hospital, China Medical University Shenyang, China.

PMID: 26131283 PMCID: PMC4483842

Abstract

OBJECTIVE: Gastric colonization by Helicobacter pylori is linked to a host of diseases, but eradication rates have declined in recent years. Some experimental studies suggest that probiotics may inhibit growth of H. pylori. This investigation was conducted to assess the impact of probiotics on both efficacy and tolerability of triple therapy to eradicate H. pylori.

METHODS: PubMed, Web of Science, and the Cochrane Collaboration were searched for relevant articles published through August 31, 2014. All analytics relied on commercially available software (Stata 11).

RESULTS: Twenty-three studies (N = 3900) qualified for meta-analysis. Pooled H. pylori eradication rates for triple therapy used alone and with added probiotics were 1464/2026 (72.26%; 95% CI, 67.66%-74.13) and 1513/1874 (80.74%; 95% CI, 74.68%-82.76%), respectively (odds ratio [OR] = 0.58; 95% CI, 0.50-0.68). Loss of appetite was similar in both groups (OR = 0.94; 95% CI, 0.61-1.45), but most adverse events (nausea, diarrhea, epigastric pain, vomiting, taste distortion, and skin rash) were mitigated through addition of probiotics. Publication bias was not evident, as indicated by Begg's and Egger's tests.

CONCLUSIONS: Probiotics may improve the efficacy of triple therapy in eradicating gastric H. pylori and alleviate most treatment-related adverse events.

Keywords: Helicobacter pylori; adverse events; eradication; probiotics; triple therapy

References

  1. Hepatogastroenterology. 2007 Oct-Nov;54(79):2032-6 - PubMed
  2. Therap Adv Gastroenterol. 2014 Jan;7(1):4-13 - PubMed
  3. J Clin Gastroenterol. 2014 May-Jun;48(5):407-13 - PubMed
  4. Eur J Clin Microbiol Infect Dis. 2011 Apr;30(4):555-9 - PubMed
  5. World J Gastroenterol. 2009 Mar 7;15(9):1119-25 - PubMed
  6. World J Gastroenterol. 2012 Nov 21;18(43):6302-7 - PubMed
  7. Helicobacter. 2007 Aug;12(4):309-16 - PubMed
  8. Aliment Pharmacol Ther. 2007 Jan 15;25(2):155-68 - PubMed
  9. Clin Vaccine Immunol. 2008 Sep;15(9):1472-82 - PubMed
  10. Gastroenterology. 2002 Dec;123(6):1763-9 - PubMed
  11. Lancet. 2003 Jan 4;361(9351):86 - PubMed
  12. Helicobacter. 2008 Aug;13(4):261-8 - PubMed
  13. J Physiol Pharmacol. 2006 Sep;57 Suppl 3:123-41 - PubMed
  14. Iran Red Crescent Med J. 2012 Oct;14(10):657-66 - PubMed
  15. PLoS One. 2013 Jul 10;8(7):e68596 - PubMed
  16. Rev Esp Enferm Dig. 2013 Sep;105(8):445-53 - PubMed
  17. J Gen Intern Med. 2005 Feb;20(2):139-42 - PubMed
  18. J Med Microbiol. 2005 May;54(Pt 5):481-3 - PubMed
  19. APMIS. 2014 Oct;122(10):941-50 - PubMed
  20. PLoS One. 2013 May 16;8(5):e63388 - PubMed
  21. Gastroenterol Hepatol Bed Bench. 2013;6(Suppl 1):S99-S104 - PubMed
  22. Eur J Gastroenterol Hepatol. 2009 Jan;21(1):45-53 - PubMed
  23. Lancet. 1988 Dec 24-31;2(8626-8627):1437-42 - PubMed
  24. Aliment Pharmacol Ther. 2001 Feb;15(2):163-9 - PubMed
  25. Aliment Pharmacol Ther. 2004 Nov 15;20(10):1181-8 - PubMed
  26. Eur Rev Med Pharmacol Sci. 2008 Jul-Aug;12(4):251-6 - PubMed
  27. Am J Gastroenterol. 2013 Feb;108(2):208-15 - PubMed
  28. J Med Food. 2011 Apr;14(4):344-7 - PubMed
  29. J Med Microbiol. 2000 Jul;49(7):635-42 - PubMed
  30. J Gastroenterol Hepatol. 2006 Sep;21(9):1399-406 - PubMed
  31. Aliment Pharmacol Ther. 2005 May 15;21(10):1263-72 - PubMed
  32. Aliment Pharmacol Ther. 2000 Dec;14(12):1625-9 - PubMed
  33. BMC Gastroenterol. 2013 Mar 26;13:56 - PubMed
  34. Am J Gastroenterol. 2002 Nov;97(11):2744-9 - PubMed
  35. Helicobacter. 2010 Jun;15(3):206-13 - PubMed
  36. Lancet. 1984 Jun 16;1(8390):1311-5 - PubMed
  37. FEMS Immunol Med Microbiol. 2011 Nov;63(2):153-64 - PubMed
  38. Am J Gastroenterol. 2007 May;102(5):951-6 - PubMed
  39. J Gastroenterol Hepatol. 2012 May;27(5):888-92 - PubMed
  40. Aliment Pharmacol Ther. 2002 Sep;16(9):1669-75 - PubMed
  41. Nat Rev Gastroenterol Hepatol. 2014 Apr;11(4):234-42 - PubMed
  42. Digestion. 2001;63(1):1-7 - PubMed
  43. Biomed Pharmacother. 2013 May;67(4):347-9 - PubMed
  44. Am J Gastroenterol. 2007 Aug;102(8):1808-25 - PubMed
  45. Int J Antimicrob Agents. 2003 Oct;22(4):360-6 - PubMed
  46. PLoS One. 2014 Apr 10;9(4):e94699 - PubMed
  47. J Clin Gastroenterol. 2013 Jan;47(1):25-32 - PubMed
  48. Aliment Pharmacol Ther. 2003 Aug 1;18(3):347-53 - PubMed
  49. PLoS One. 2014 Mar 03;9(3):e90153 - PubMed
  50. Antimicrob Agents Chemother. 2001 Nov;45(11):3156-61 - PubMed

Publication Types